{"nctId":"NCT02245360","briefTitle":"Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis","startDateStruct":{"date":"2014-10"},"conditions":["Seasonal Allergic Rhinitis"],"count":107,"armGroups":[{"label":"Grass tablet 75,000 SQ-T","type":"EXPERIMENTAL","interventionNames":["Drug: Phleum pratense grass pollen allergen extract"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"Phleum pratense grass pollen allergen extract","otherNames":["GRAZAX/GRASTEK"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* clinical history consistent with grass pollen-induced allergic rhinoconjunctivitis.\n* Use of symptomatic treatment of grass pollen-induced allergic rhinoconjunctivitis.\n* Positive skin prick test response (wheal diameter ≥3 mm) to Phleum pratense.\n* If asthma, daily use of Inhaled corticosteroid (ICS) should be ≤400 microgram budesonide or equivalent\n* Moderate or higher level of Phleum pratense specific IgE (Immunoglobulin E) (defined as ≥IgE Class 2; or ≥0.70 Kilo Units/liter (kU/L))\n\nExclusion Criteria:\n\n* Reduced lung function (defined as FEV1 \\< 70% (FEV1=Forced Expiratory Volume in 1 second) of predicted value after adequate pharmacologic treatment) measured at Visit 1 and Visit 2\n* Clinical history of uncontrolled asthma within 3 months prior to the screening visit","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Primary Efficacy Endpoint is Change From Baseline to End of Treatment of Phleum Pratense Specific Immunoglobulin G4 (IgG4) in Serum","description":"measurement of IgG4 in serum","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.684","spread":"1.691"},{"groupId":"OG001","value":"0.050","spread":"0.588"}]}]}]},{"type":"SECONDARY","title":"Change of Phleum Pratense Specific Immunoglobulin E (IgE) From Baseline to End of Treatment","description":"measurement of IgE in serum","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.751","spread":"29.364"},{"groupId":"OG001","value":"-2.756","spread":"16.933"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":53},"commonTop":["Throat irritation","Oral pruritus","Respiratory tract infection viral","Tongue oedema","Ear pruritus"]}}}